(PA-332) Clinical Study on the Efficacy and Safety of Aponermin Combined with Dexamethasone-Based Regimen in Multidrug-Resistant Multiple Myeloma

A retrospective analysis was conducted on clinical data from 26 patients with relapsed/refractory MM treated at The First Affiliated Hospital of Sun Yat-sen University between October 1, 2024, and April 30, 2025. Data included demographic characteristics, R-ISS staging, M-protein subtype, light chain type, cytogenetic abnormalities, and prior treatment regimens. Enrolled patients had received 2–5 prior lines of therapy. The efficacy and safety of the aponermin plus dexamethasone-based regimen were evaluated.

Results:   Among the 26 patients, 65.38% were male, with a median age of 64 years (range: 50–79). R-ISS stages II–III predominated (23/26, 88.5%). The most common M-protein subtypes were IgG (9/26, 34.6%) and IgA (5/26, 19.2%). Cytogenetic abnormalities included 1q21 amplification (14/26, 53.8%) and t(4;14) (6/26, 23.1%). All patients had received 2–5 prior lines of therapy. Following treatment with the aponermin -dexamethasone-based regimen, 17 patients (65.4%) achieved ≥ partial response (PR), 1 patient (3.8%) had stable disease (SD), 3 patients (11.5%) experienced disease progression (PD), and 4 patients (15.4%) were not yet evaluable. Transient transaminase elevation occurred in 2 patients (7.7%), which resolved after hepatoprotective therapy.

Conclusions:   

The aponermin combined with dexamethasone-based regimen demonstrated high efficacy and good tolerability in patients with multidrug-resistant MM. For patients ineligible for immunotherapy, this regimen represents a promising therapeutic option worthy of further exploration.